Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874989 · ClinicalTrials.gov registry record · Phase 1
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02874989 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 26 participants.
The verdict
NCT02874989, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days in 3 consecutive weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin (1250 mg/d) will be safe and well tolerated in patients with IPF. Treatment with D+Q will result in reduced abundance of pro-inflammatory cells within subjects over baseline. Finally, the reduction in biomarkers of cellular pro-inflammatory state will be related to no change in functional and patient reported outcomes.
Interventions
- DRUG Placebo
- DRUG Dasatinib + Quercetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2019-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02874989
The ClinicalTrials.gov registry entry for NCT02874989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02874989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02874989 about?
NCT02874989 is a clinical study titled "Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial". The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days in 3 consecutive weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin (1250 mg/d) will be safe and well tolerated in patients with IPF. Treatment with D+Q will result in reduced abundanc...
What is the current status of trial NCT02874989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2016-12-16. Estimated completion is 2019-06-03.
What interventions are being tested in trial NCT02874989?
The interventions under investigation include: Placebo (DRUG), Dasatinib + Quercetin (DRUG).
Who is sponsoring clinical trial NCT02874989?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.